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Structured Abstract  
Aims: The indications for renal biopsy in type 2 diabetes mellitus (T2D) are not 
well established. We investigated the prevalence, spectrum, and predictors of 
biopsy-proven non-diabetic renal disease (NDRD) in T2D. 
Methods: An observational, single-centre, retrospective study of T2D adults who 
underwent renal biopsies (N=51) over 10 years for nephrotic-range proteinuria, 
microscopic haematuria, or rapidly declining renal function.  
Results: Thirty-five (68.6%) biopsies were diagnostic of NDRD, and 16 (31.4%) 
revealed isolated diabetic nephropathy. The most common NDRDs were interstitial 
nephritis (20%), progressive crescentic glomerulonephritis (14%), membranous 
nephropathy (11%), and focal segmental glomerulosclerosis (11%). The odds for 
NDRD declined by 97% in the presence of diabetic retinopathy (P<0.001). The 
deterioration of HbA1c during the year before biopsy predicted NDRD even after 
adjusting for diabetic retinopathy (OR, 7.65; 95% CI, 1.36-123.04; P=0.003). A 
model based on the interaction between the HbA1c values 12 months before 
biopsy and the absolute change in these values during the preceding year 
predicted NDRD with 73.7% sensitivity and 75% specificity (AUC, 0.77; 95% CI, 
0.59-0.94).  
Conclusions: This study demonstrated a considerably high prevalence of NDRD 
in T2D adults undergoing renal biopsy. The absence of diabetic retinopathy, lower 
HbA1c values 12 months before biopsy and greater deterioration in HbA1c prior to 
biopsy predicted NDRD in T2D. Further studies are needed to validate the findings. 
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1. Introduction 
Diabetic nephropathy (DN) is a major microvascular complication of diabetes 
mellitus associated with end-stage renal disease requiring renal replacement 
therapy. A major contributor to development and progression of DN is glycaemic 
control as shown by major diabetes studies1,2. Other modifiable factors for DN 
include hypertension, obesity, smoking, and dyslipidaemia3. There is encouraging 
evidence suggesting that timely and long-term tight glycaemic control effectively 
delays the onset and slows the progression of DN in both type 1 and type 2 
diabetes4,5. 
The diagnosis of DN is usually made through biochemical analyses of urine and 
blood. An early manifestation is persistent microalbuminuria. Estimated glomerular 
filtration rate (eGFR) declines prior to more severe macroalbuminuria in type 2 
diabetes (T2D); hence a combination of eGFR and albuminuria can be used to 
stage and monitor patients6,7. While diabetes is the major cause of renal disease in 
patients with diabetes, in about a third of patients, renal dysfunction is due to other 
causes (non-diabetic renal disease; NDRD)8-17. In the NDRD group, the treatment 
of renal disease may require a different strategy. A renal biopsy is helpful in 
determining the underlying pathophysiology in NDRD.  
The selection criteria for renal biopsy in diabetic patients are not well established. 
In type 1 diabetes, the presence of proteinuria with short diabetes duration and/or 
rapidly declining renal function, especially in the absence of diabetic retinopathy, 
have been suggested as a signal for the need for renal biopsy18. In T2D, the 
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criteria are less clear since dysglycaemia is present for many years prior to 
diagnosis. Commonly, proteinuria > 1 g/24 hours, renal involvement without 
diabetic retinopathy, or unexplained haematuria have been used as indicators for 
renal biopsy19. Identification of novel predictors of renal disease will improve the 
current selection criteria for renal biopsy and facilitate early detection of NDRD in 
T2D. Early diagnosis and appropriate treatment may help slow progression to end 
stage renal disease. In this study, we sought to investigate the prevalence, 
spectrum, and predictors of biopsy-proven NDRD in adults with T2D.  
 
2. Subjects, Material and Methods 
This was a retrospective observational study of T2D patients who underwent renal 
biopsies over 10 years in our centre. As this was an audit of retrospective data, the 
local research ethics committee felt that no formal ethics approval was required.  
Fifty-one native renal biopsies obtained from 51 adults with a documented 
diagnosis of T2D, referred to our centre between 2002 and 2012, were analysed. 
In our centre, as a policy, DN is diagnosed on clinical grounds and kidney biopsies 
are only carried out if there are atypical clinical features. Indications for biopsy, in 
this cohort, included nephrotic range proteinuria (> 3 g/24 hours), significant 
microscopic haematuria (≥ ++), or rapidly declining renal function. Renal biopsy 
specimens were examined by light microscopy, direct immunofluorescence, and 
electron microscopy, where indicated.  
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The biopsy report, biochemical results, and clinical information at the time of renal 
biopsy and follow-up were studied. Glomerular filtration rate estimates were 
calculated using the 4-variable Modification of Diet in Renal Disease Study 
equation20. Glycaemic control was assessed by glycated haemoglobin (HbA1c) 
levels, measured using National Glycohemoglobin Standardization Program 
(NGSP) certified method, standardized to the Diabetes Control and Complications 
Trial assay. HbA1c values are reported in both NGSP percentage units with 
International Federation of Clinical Chemistry (IFCC) units (mmol/mol) in 
parentheses. 
The primary outcome measure was the prevalence and nature of histologically-
proven NDRD. The secondary outcome measures included predictors of NDRD vs. 
DN and the risk factors for adverse renal outcome. Adverse renal outcomes 
included reaching end stage renal disease requiring renal replacement therapy or 
chronic kidney disease (CKD) leading to death, or a composite of the two. 
 
2.1 Statistical Analyses 
The Shapiro–Wilk test was applied to assess normality of data distribution. 
Continuous variables with normal distribution are presented as means ± standard 
deviation (SD) and compared using the Student’s t test. Continuous variables with 
non-normal distribution are presented as medians and interquartile ranges (IQR) 
and compared using the Wilcoxon rank-sum test or the Wilcoxon-matched pairs 
signed-ranks test. The chi-square test was applied to examine patterns between 
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categorical variables. Univariate and multivariate standard and exact logistic 
regression modelling were employed to identify the association between biopsy-
proven NDRD and potential predictors. The logistic regression models were fitted 
using a stepwise bidirectional elimination algorithm, with inclusion and exclusion 
criteria of P≤0.15 and P≥0.2 respectively.  
The number in whom complete data was available is mentioned in the text. 
Absolute changes (Δ) in eGFR and in HbA1c were calculated by subtracting values 
12 months before biopsy from those at the time of biopsy. The follow-up ΔeGFR 
were calculated by subtracting the eGFR values at the time of biopsy from the 
values 12 months after.  
Findings were considered to be statistically significant at the 5% level. Statistical 
calculations were performed using Stata 11.2 Special Edition (StataCorp LP, 
College Station, TX). 
 
3. Results  
3.1 Sample Characteristics and Renal Biopsy Findings 
The entire cohort of renal biopsy patients (N=51) was predominantly male (64.7%), 
of mixed ethnicity (28 White Europeans, 18 South-Asians, 3 African Caribbeans, 2 
with “not stated” ethnicity), aged 61 ± 12 years (mean ± SD). The median (IQR) 
duration of T2D was 9 (2-15) years (N=45). At the time of renal biopsy, the NGSP 
HbA1c was 7.2 (6.4-7.8) %, the IFCC HbA1c 55 (46-62) mmol/mol (N=42). Twenty-
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two of 39 (56.4%) patients had diabetic retinopathy. The median (IQR) eGFR was 
23.5 (11-39.5) ml/min/1.73m2, and 60.4% of patients had stage 4–5 CKD. Twenty-
one of 36 (58.3%) proteinuric patients had nephrotic range proteinuria 
(albumin/creatinine ratio > 250 mg/mmol or protein/creatinine ratio > 300 
mg/mmol), and 16 of 35 (45.7%) had microscopic haematuria. Thirty-four of 46 
(73.9%) patients were on renin-angiotensin-aldosterone system (RAAS) blockade 
therapy. 
Thirty-five (68.6%) biopsies were diagnostic of NDRD, 16 (31.4%) revealed 
isolated DN, and 4 (7.8%) showed NDRD superimposed on DN. The spectrum of 
NDRD was as follows: interstitial nephritis 7 (20%), progressive crescentic 
glomerulonephritis 5 (14.3%), membranous nephropathy 4 (11.4%), focal 
segmental glomerulosclerosis 4 (11.4%), acute tubular necrosis 3 (8.6%), 
immunoglobulin A nephropathy 2 (5.7%), ischaemic nephropathy 2 (5.7%), minimal 
change nephropathy 1 (2.9%), minimal change nephropathy + interstitial nephritis 
1 (2.9%), mesangiocapillary glomerulonephritis 1 (2.9%), amyloidosis  1 (2.9%), 
oxalate nephropathy 1 (2.9%), myeloma cast nephropathy 1 (2.9%), fibrillary 
glomerulonephritis 1 (2.9%), and collagenofibrotic glomerulopathy 1 (2.9%). In 
more than 50% of NDRD, histology prompted alteration in therapeutic 
management.  
Table 1 shows characteristics of the two subgroups based on renal biopsy findings. 
The patients with NDRD had better glycaemic control 12 months before biopsy 
(N=32), a smaller decrease in HbA1c during the year before biopsy (N=31; Figure 
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1A, Figure 1B), and a lower rate of diabetic retinopathy than those with isolated 
DN. There was a trend towards more South-Asians in the DN subgroup. We did 
not find any difference in eGFR prior to biopsy, at the time of biopsy, and 12 
months after biopsy between the two subgroups. Following the therapeutic 
adjustments based on renal biopsy findings, the patients with NDRD had 
significantly greater improvement in eGFR 12 months after biopsy (N=38) than 
patients with isolated DN (Table 1). Similar numbers received RAAS blockade 
therapy in the two subgroups. There were no differences in duration of T2D (N=45) 
and in pharmacological treatment of diabetes (N=47; Table 1).  
By the end of 2012, overall mortality was 29.4% with no difference between the 
subgroups. There was no difference in number of patients requiring renal 
replacement therapy. However, a composite adverse renal outcome (reaching end 
stage renal disease requiring renal replacement therapy + CKD leading to death; 
N=48) was higher in isolated DN subgroup (Table 1). 
 
3.2 Predictors of Renal Disease and Risk Factors for Adverse Renal Outcomes 
Table 2 presents the results of a univariate exact logistic regression analysis for 
unadjusted (crude) associations between NDRD and independent variables with 
odds ratios (OR), 95% confidence intervals (95% CI), and P-values. For subjects 
with diabetic retinopathy, the expected log odds of having NDRD decreased by 
3.39, and the odds for NDRD declined by 97% (P<0.001). The unadjusted OR of 
the association between NDRD and HbA1c 12 months before biopsy was 0.60; for 
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every 1% (10.9 mmol/mol) increase in the HbA1c 12 months before biopsy, the 
odds for NDRD declined by 40% (P=0.018). There was a trend towards higher 
odds for NDRD with deterioration of HbA1c during the year before biopsy 
(P=0.054). We also observed a trend towards higher odds for NDRD with the 
increasing INTHbA1c (a variable consistent with the interaction between HbA1c 12 
months before biopsy and ΔHbA1c during the year before biopsy); P=0.069. 
The association between NDRD and deterioration of HbA1c during the year before 
biopsy remained significant even after adjusting for diabetic retinopathy in the final 
multivariate regression model (OR 7.65; 95% CI, 1.36 to 123.04; P=0.003). Our 
results further showed a statistically significant joint distribution of diabetic 
retinopathy and INTHbA1c. After adjusting for the diabetic retinopathy, the 
expected odds for NDRD increased by 1.28 for every one unit (1%) increase in 
INTHbA1c (OR 1.28; 95% CI, 1.03 to 1.82; P=0.013). 
Figure 2 shows estimated predicted probabilities of having NDRD, by the HbA1c 
12 months before biopsy, ranging from an approximately 85% probability of having 
NDRD in patients with a relatively low preceding HbA1c to a < 50% probability in 
patients with HbA1c of > 8.5% (69 mmol/mol). Of importance, the patients who 
experienced deterioration in HbA1c during the year prior to biopsy had at least 
63% probability of having NDRD (Figure 2, plus symbols). The HbA1c 12 months 
before biopsy in these patients was < 8% (64 mmol/mol). 
To further define the importance of HbA1c in predicting the NDRD, we performed 
receiver operating characteristic (ROC) curve analysis of three HbA1c-based 
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predictive models for NDRD (Figure 3). In the first model, the HbA1c 12 months 
before biopsy was used. The cut point of the HbA1c 12 months before biopsy of ≥ 
6.2% (44 mmol/mol) was the best predictor of NDRD with 100% sensitivity. 
However, the 17% specificity reflected high rate (83%) of false positives (area 
under the curve AUC, 0.29; 95% CI, 0.07 to 0.51). In the second model, we 
measured predictive accuracy of the ΔHbA1c during the year prior to biopsy. The 
ΔHbA1c during the year prior to biopsy of ≥ -0.4% (-4.4 mmol/mol) was the best 
predictor of NDRD (73.7% sensitivity, 66.7% specificity; AUC, 0.75; 95% CI, 0.56 
to 0.93). Since the preceding HbA1c and the ΔHbA1c during the year before 
biopsy are closely interrelated, the third predictive ROC curve model included an 
interaction term between the two aforementioned predictors (INTHbA1c; INTHbA1c 
= HbA1c 12 months before biopsy * ΔHbA1c during the year before biopsy). The 
ROC curve analysis showed that the INTHbA1c cut-off of ≥ -2.48% (-27.1 
mmol/mol) was the best predictor of NDRD with 73.7% sensitivity and 75% 
specificity (AUC, 0.77; 95% CI, 0.59 to 0.94; Figure 3). 
 
4. Discussion 
There were three major findings in the present study First, renal biopsies with 
histological confirmation of renal involvement revealed a considerably high 
prevalence of NDRD in a cohort of T2D patients with significant dipstick 
haematuria, nephrotic range proteinuria, and/or rapidly declining renal function. 
Second, this study confirmed the previously recognized associations between poor 
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long-term glucose control and presence of diabetic retinopathy and DN in T2D2. 
Third, besides the previously identified predictors of NDRD that include new onset 
nephrotic range proteinuria, shorter duration of diabetes, and the absence of 
diabetic retinopathy21-23, this is the first study to demonstrate that in T2D, the 
HbA1c 12 months before biopsy and the absolute change in HbA1c during the year 
before biopsy predict the type of renal disease. This study also shows that those 
with biopsy-proven NDRD have a better composite outcome of end stage renal 
disease and death. 
Our finding of high prevalence of NDRD in T2D is consistent with observations 
made by others8-17. These studies showed a variable prevalence of NDRD of 18-
78%. This is attributed to selection criteria for renal biopsy and to the geographical 
and ethnic differences in the incidence of various NDRD. The finding of high 
prevalence of NDRD in this cohort of T2D patients with renal impairment and 
atypical features has important clinical implications; at least 50% of patients had 
NDRD that was treatable with steroids and immunosuppressive agents. The 
therapeutic adjustments based on histology and resultant modification of course of 
NDRD may explain the improvement in eGFR and the better composite adverse 
renal outcome in the NDRD subgroup. By contrast, there is no specific treatment 
for isolated DN3,6,7. Early and accurate diagnosis of NDRD is important for diabetic 
patients since treatment and prognosis may vary according to the underlying 
cause. 
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Several recent cross-sectional and longitudinal studies have reported associations 
between HbA1c and kidney function in T2D with mixed results24-29. Lee and 
colleagues24 demonstrated a negative effect of preceding HbA1c (recorded 1 year 
before) on eGFR in T2D patients with CKD stages 3 and 4. In our study, a trend 
towards the positive association between the HbA1c 12 months before biopsy and 
eGFR was observed in the subgroup with isolated DN (r=0.56; P=0.058; N=12). 
There was no association between the preceding HbA1c and eGFR even after the 
patients were grouped according to CKD stages. Of importance, our results show 
that both the HbA1c 12 months before biopsy and the absolute change in HbA1c 
during the year before biopsy differ between patients with isolated DN and NDRD 
with similarly decreased eGFR at the time of renal biopsy. Our study is consistent 
with previous observations that annual variation in HbA1c could predict DN in 
patients with T2D and that long-term variability of HbA1c predicts 
microalbuminuria26,27 and development/progression of renal and cardiovascular 
complications of T2D28,29.  
The ROC curve analysis of the three proposed HbA1c-based predictive models 
showed that although both the HbA1c 12 months before biopsy and its change 
during the year before biopsy predicted type of renal disease, the model based on 
the interaction between the two variables (INTHbA1c) had the best predictive 
accuracy for NDRD. Since different predictors may be sensitive to different aspects 
of renal diseases, this “new” predictor may improve the overall predictive capability 
of the HbA1c-based models.  
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In the present study, the patients histologically diagnosed with NDRD had fairly 
good long-term diabetes control 12 months prior to biopsy. Our findings indicate 
that the HbA1c either remains stable or gradually deteriorates in patients with 
NDRD despite the decline in renal function during the year prior to renal biopsy. 
This observation may be explained by the adverse impact of inflammatory and 
immune responses to progressive NDRD on glucose control. Both acute and 
chronic inflammation leads to stress hyperglycaemia, consistent with a maladaptive 
and detrimental response to stress and inflammation30.  Furthermore, in patients 
with isolated DN, the elevated preceding HbA1c levels improved significantly 
during the year before renal biopsy. Decreased renal degradation of insulin 
typically ensues later in the course of CKD31, which could account for the 
“improved” glucose control prior to biopsy in patients with isolated DN. 
There are several limitations to our study that should be considered in relation to 
the findings. The relatively small sample size and retrospective nature precluded 
examination of influence of ethnicity, arterial hypertension, anaemia, smoking, and 
others. Data on some clinical variables and characteristics were not available for 
some patients and thus could not be included in our analyses. The exact stages of 
diabetic retinopathy could not be established in each case to further correlate with 
the type of renal disease. A final limitation concerns the applicability of the results 
to practical decision making in the general diabetic population, as only T2D adults 
with suspicion of underlying NDRD were enrolled.  
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Despite these limitations, our study demonstrates a considerably high prevalence 
of histologically-proven NDRD in T2D adults undergoing renal biopsy. It also shows 
the HbA1c levels during the year before renal biopsy differ between NDRD and 
isolated DN. Besides the predictive value of diabetic retinopathy, we have identified 
the HbA1c 12 months before biopsy and ΔHbA1c as important novel candidate 
predictors of NDRD and DN in T2D. While HbA1c remains the best long-term 
marker of glycaemic control in patients with T2D, our findings suggest that annual 
evaluation of HbA1c and its dynamic changes along with the assessment of 
diabetic retinopathy could facilitate early detection of NDRD in T2D. Clinical 
significance of this finding is emphasized by the fact that the selection criteria for 
renal biopsy in T2D adults are still not well established and novel predictors of 
renal disease are critically needed. Prospective studies are needed to validate the 
proposed HbA1c-based predictive models for NDRD with a view to refining the 
current selection criteria for renal biopsy in T2D patients, and identify patients that 
will benefit from specific therapeutic interventions that will reduce adverse renal 
outcomes. 
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Tables 
Table 1: Characteristics of patients (N=51) according to renal biopsy findings 
Variable 
Patients with 
NDRD (N=35) 
Patients with 
isolated DN 
(N=16) 
P 
Age (years) 63 ± 11 58 ± 14 0.167 
Sex - females (%) 40 25 0.298 
South-Asian ethnicity (%) 30.3 61.5 0.051 
Duration of diabetes (years) 7.5 (1-13) 9 (4-19) 0.433 
Diabetes treatment - diet only (%) 9.4 6.7 0.757 
Diabetes treatment - OHA/GLP-1 agonists (%) 53.1 66.7 0.382 
Diabetes treatment - insulin/insulin + OHA (%) 37.5 26.7 0.465 
HbA1c at the time of biopsy 
    - NGSP HbA1c (%) 
    - IFCC HbA1c (mmol/mol) 
7.2 ± 0.88 
55 ± 9.6 
7.7± 1.76 
61 ± 19.2 0.188 
HbA1c 6 months before biopsy 
    - NGSP HbA1c (%) 
    - IFCC HbA1c (mmol/mol) 
7.4 (6.3-8.0) 
57 (45-64) 
8.9 (6.6-12.2) 
74 (48-110) 0.288 
HbA1c 12 months before biopsy 
    - NGSP HbA1c (%) 
    - IFCC HbA1c (mmol/mol) 
6.9 (6.5-8.0) 
52 (48-64) 
9 (7.2-10.6) 
75 (55-92) 0.047 
ΔHbA1c during the year before biopsy 
    - NGSP HbA1c (%) 
    - IFCC HbA1c (mmol/mol) 
-0.1 (-0.5; +0.3) 
-1.1 (-5.5; +3.3) 
-0.9 (-1.75; -0.3) 
-9.8 (-19.1; -3.3) 0.023 
Diabetic retinopathy (%) 34.6 100 <0.001 
eGFR 12 months before biopsy 
(ml/min/1.73m
2
) 
58 (40-77)   55 (46-63)   0.648 
eGFR 6 months before biopsy (ml/min/1.73m
2
) 45 (39-81) 41 (28-56) 0.244 
eGFR at the time of biopsy (ml/min/1.73m
2
) 16 (10-36) 29 (17-49) 0.158 
eGFR 6 months after biopsy (ml/min/1.73m
2
) 33 (17-47.5) 28.5 (18-36) 0.550 
eGFR 12 months after biopsy (ml/min/1.73m
2
) 37.8 ± 22 32.1 ± 24.4 0.318 
ΔeGFR during the year before biopsy 
(ml/min/1.73m
2
) 
-31.3 ± 25.8 -21.1 ± 16 0.233 
ΔeGFR 12 months after biopsy 
(ml/min/1.73m
2
) 
6.8 ± 17.4 -7.1 ± 16.4 0.015 
Urine PCR at the time of biopsy (mg/mmol) 367 (265-1015) 441 (130.5-871) 0.685 
RAAS blockade therapy at the time of biopsy 
(%) 
74.2 73.3 0.950 
Adverse renal outcome (%) 34.4 68.8 0.024 
-- Renal replacement therapy after biopsy (%) 18.2 25 0.579 
-- Mortality (%) 
   - the time until death (months) 
22.9 
29 ± 22.9 
43.8 
24 ± 27.4 
0.129 
0.738 
Continuous variables with normal distribution are presented as means ± SD. Continuous variables 
with non-normal distributions are presented as medians (IQR). DN, diabetic nephropathy; eGFR, 
glomerular filtration rate estimates; ΔeGFR, an absolute change in eGFR; GLP-1, glucagon-like 
peptide-1; HbA1c, glycated haemoglobin; ΔHbA1c, an absolute change in HbA1c; IFCC, 
International Federation of Clinical Chemistry; NDRD, non-diabetic renal disease; NGSP, National 
Glycohemoglobin Standardization Program; OHA, oral hypoglycemic agents; PCR, Protein to 
Creatinine Ratio; RAAS, renin-angiotensin-aldosterone system. 
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Table 2: Unadjusted (crude) associations between non-diabetic renal disease 
and independent variables 
Variable  P-value OR 95% CI 
Age 0.171 1.04 0.99 to 1.09 
Sex    
 female  1.00 (reference)  
 male 0.474 0.51 0.10 to 2.14 
Ethnicity    
 White European  1.00 (reference)  
 South-Asian 0.107 0.28 0.06 to 1.25 
Duration of diabetes 0.493 0.97 0.89 to 1.06 
Diabetes treatment    
 diet only  1.00 (reference)  
 OHA/GLP-1 agonists 0.607 0.53 0.05 to 5.86 
 insulin/insulin + OHA 0.950 1.08 0.09 to 13.54 
HbA1c 12 months before biopsy 0.018 0.60 0.35 to 0.93 
HbA1c at the time of biopsy 0.200 0.71 0.41 to 1.19 
ΔHbA1c during the year before biopsy 0.054 1.89 0.99 to 4.46 
INTHbA1c 0.069 1.06 1.00 to 1.14 
Diabetic retinopathy <0.001 0.03 0.00 to 0.24 
eGFR 12 months before biopsy 0.401 1.02 0.98 to 1.06 
eGFR at the time of biopsy  0.374 0.99 0.96 to 1.02 
ΔeGFR during the year before biopsy 0.211 0.98 0.94 to 1.01 
Microscopic hematuria 0.116 4.86 0.75 to 56.13 
Nephrotic proteinuria 1.000 1.02 0.19 to 5.17 
Urine PCR at the time of biopsy 0.384 1.00 1.0 to 1.0 
RAAS blockade therapy at the time of 
biopsy 
1.000 1.04 0.19 to 5.03 
CI, confidence interval; eGFR, glomerular filtration rate estimates; ΔeGFR, an absolute 
change in eGFR; GLP-1, glucagon-like peptide-1; HbA1c, glycated haemoglobin; ΔHbA1c, 
an absolute change in HbA1c; INTHbA1c, a variable consistent with the interaction 
between HbA1c 12 months before biopsy and ΔHbA1c during the year before biopsy; 
OHA, oral hypoglycemic agents; OR, odds ratio; PCR, Protein to Creatinine Ratio; RAAS, 
renin-angiotensin-aldosterone system. 
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Figures 
Figure 1A: Long-term glucose control in type 2 diabetic patients with isolated 
diabetic nephropathy vs. non-diabetic renal disease 
 
 
HbA1c, glycated haemoglobin; NGSP, National Glycohemoglobin Standardization 
Program. 
  
N
G
S
P
 H
b
A
1
c
 [
%
]
P=0.047
N=12 N=8 N=15
P=0.02
N=20 N=19 N=275
6
7
8
9
1
0
1
1
1
2
1
3
1
4
1
5
Isolated diabetic nephropathy Non-diabetic renal disease
HbA1c 12 months before renal biopsy
HbA1c 6 months before renal biopsy
HbA1c at the time of renal biopsy
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
26 
 
Figure 1B: Changes in HbA1c during the year before renal biopsy in patients 
with isolated diabetic nephropathy vs. non-diabetic renal disease 
 
 
HbA1c, glycated haemoglobin; ΔHbA1c, an absolute change in HbA1c; NGSP, National 
Glycohemoglobin Standardization Program. 
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Figure 2: Predicted probabilities of having non-diabetic renal disease in type 
2 diabetes, by the HbA1c 12 months before biopsy 
 
 
HbA1c, glycated haemoglobin; ΔHbA1c, an absolute change in HbA1c; NDRD, non-
diabetic renal disease; NGSP, National Glycohemoglobin Standardization Program. 
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Figure 3: ROC curve of the three HbA1c-based predictive models for non-
diabetic renal disease 
 
HbA1c, glycated haemoglobin; ΔHbA1c, an absolute change in HbA1c during the year 
prior to biopsy; INTHbA1c, an interaction term between the HbA1c 12 months before 
biopsy predictor and the ΔHbA1c during the year before biopsy predictor; NDRD, non-
diabetic renal disease; ROC, receiver operating characteristic. 
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